产品
编 号：F759971
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 728917-18-8
产品详情
生物活性：
Veltuzumab (IMMU-106) is a humanized anti-CD20 monoclonal antibody. Veltuzumab has low EC50 value of 0.08-0.09 μg/mL in the Daudi cell line. Veltuzumab can be used for the research of cancer including non-Hodgkin lymphoma (NHL).
体内研究：
Veltuzumab (i.v. or s.c.; 5, 20 and 60 μg; single) can control tumor growth or deplete circulating or sessile B cells at low doses in mouse models of intraperitoneal and subcutaneous doses. Veltuzumab (i.p.; 0.05-35 μg) are significantly effective in vivo.Animal Model:Lymphoma xenograft model
Dosage:5, 20 and 60 μg
Administration:intraperitoneal and subcutaneous, single
Result:Showed low dose of 0.05 μg increased the MST.
Animal Model:SCID mice
Dosage:0.5, 0.25, 0.1, or 0.05 μg; 35, 3.5, 0.35, or 0.035 μg
Administration:intraperitoneal, single
Result:Improved significantly survival.
体外研究：
Veltuzumab significantly reduces off-rates in human lymphoma cell lines, as well as increases complement-dependent cytotoxicity in 1 of 3 cell lines, but no other in vitro differences.Veltuzumab (0.001-10 μg/mL, 3 h) has low EC50 value of 0.08-0.09 μg/mL in the Daudi cell line.
Veltuzumab (IMMU-106) is a humanized anti-CD20 monoclonal antibody. Veltuzumab has low EC50 value of 0.08-0.09 μg/mL in the Daudi cell line. Veltuzumab can be used for the research of cancer including non-Hodgkin lymphoma (NHL).
体内研究：
Veltuzumab (i.v. or s.c.; 5, 20 and 60 μg; single) can control tumor growth or deplete circulating or sessile B cells at low doses in mouse models of intraperitoneal and subcutaneous doses. Veltuzumab (i.p.; 0.05-35 μg) are significantly effective in vivo.Animal Model:Lymphoma xenograft model
Dosage:5, 20 and 60 μg
Administration:intraperitoneal and subcutaneous, single
Result:Showed low dose of 0.05 μg increased the MST.
Animal Model:SCID mice
Dosage:0.5, 0.25, 0.1, or 0.05 μg; 35, 3.5, 0.35, or 0.035 μg
Administration:intraperitoneal, single
Result:Improved significantly survival.
体外研究：
Veltuzumab significantly reduces off-rates in human lymphoma cell lines, as well as increases complement-dependent cytotoxicity in 1 of 3 cell lines, but no other in vitro differences.Veltuzumab (0.001-10 μg/mL, 3 h) has low EC50 value of 0.08-0.09 μg/mL in the Daudi cell line.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备